Since no selective antiviral treatment for COVID-19 has been developed yet, although a high priority is given from the perspectives of world scientists, it is hypothesized that COVID-19 patients treated with LPV/RTV inheriting ABCB1 pharmacogene in general and in particular the ABCB1 C3435T genetic polymorphism might be predisposed to either therapeutic failure or toxicity of this antiviral therapy in a considerable proportion of patients. Here, ABCB1 is linked to COVID-19.